Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 9, Issue 1, 2000, Pages 5-12

  Kleiman, Neal S ^a,g   Tracy, Russell P ^b   Talley, J David ^c   Sigmon, Kristina ^e   Joseph, Diane ^e   Topol, Eric J ^d   Califf, Robert M ^e   Kitt, Michael ^f   Ohman, E Magnus ^e  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

^g MS F 1090 ^*  (United States)

Author keywords

Eptifibatide; Glycoprotein IIb IIIa; Myocardial infarction; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALTEPLASE; ANTITHROMBIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOPEPTIDE A; HEPARIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0033980788     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018650123272     Document Type: Article

References (29)

1. Swords NA, Mann KG. The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thrombo 1993;13:1602-1612.
2. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988;57:915-956.
3. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissuetype plasminogen activator. J Am Coll Cardiol 1992;19: 1065-1069.
4. Winters KJ, Santoro SA, Miletich JP, et al. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991;84:1552-1560.
5. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979;254:5357-5363.
6. Coller BS, Folts JD, Scudder LE, et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-786.
7. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77:670-677.
8. Kohmura C, Gold HK, Yasuda T, et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 1993;13:1837-1842.
9. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
10. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue- plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95: 846-854.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:723-725.
12. Chesebro J, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) Trial. Phase 1: A comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154.
13. Cushman M, Psaty B, Bovill E, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vase Biol 1998;16:1163-1169.
14. Bovill E, Terrin M, Stump D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1998;115: 256-265.
15. Bovill E, Granger C, Woodlief L, et al. Measures of thrombin activity in the GUSTO trial: Relationship to thrombolytic agent and mode of heparin administration. J Am Coll Cardiol 1998;21:137A.
16. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988;263:3823-3834.
17. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992;85:1706-1712.
18. Billy D, Briede J, Heemskerk JM, et al. Prothrombin conversion under flow conditions by prothrombinase assembled on adherent platelets. Blood Coagu Fibrinoly 1997;8: 168-174.
19. Harker LA. The role of platelets in the early and late vascular responses initiated by mechanical vascular injury. Fibrinoly Proteoly 1997;11:1-103.
20. Moyer MP, Tracy RP, Tracy PB, et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vase Biol 1998;18:458-465.
21. Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity - A comparison with Scott syndrome. Blood 1997;89:1599-1611.
22. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 anti-body. J Clin Invest 1996;98:863-874.
23. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and lowdose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1991;324:1217-1218.
24. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infaction. Am J Cardiol 1990;66:1412-1417.
25. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial, B Heart J 1992;67:122-128.
26. Antman EM. Hirudin in acute myocardial infarction -thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
27. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy -results from the GUSTO-1 trial. Circulation 1996;94:1826-1833.
28. Collen D, Lu HR, Stassen JM, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Hαemost 1994;71:95-102.
29. Bugiardini R, Pozzati A, Borghi A, et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome. Am J Cardiol 1991;67:460-464.